NASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $11.15 -0.13 (-1.15%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get EYPT alerts:Sign Up Key Stats Today's Range$10.95▼$11.3550-Day Range$7.58▼$11.2852-Week Range$5.67▼$30.99Volume519,897 shsAverage Volume922,320 shsMarket Capitalization$580.74 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingBuy Company OverviewEyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, EyePoint Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreEYPT MarketRank™: EyePoint Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 617th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyePoint Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about EyePoint Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.33) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about EyePoint Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.15% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently decreased by 1.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.15% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently decreased by 1.87%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.83 News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest5 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,997.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.74% of the stock of EyePoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about EyePoint Pharmaceuticals' insider trading history. Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Stock News HeadlinesScotiabank Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Sector Outperform RecommendationOctober 17 at 7:24 PM | msn.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 16 at 7:00 AM | globenewswire.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 17, 2024 | Porter & Company (Ad)EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $30.57 Average Target Price from AnalystsOctober 7, 2024 | americanbankingnews.comEyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of DirectorsSeptember 4, 2024 | globenewswire.comJefferies Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy RecommendationAugust 29, 2024 | msn.comFDA warns Watertown biotech over ‘significant violations’ at manufacturing facilityAugust 29, 2024 | bizjournals.comEyePoint Pharmaceuticals: A Buy Rating with a $15 Price Target Amid Promising Duravyu Prospects and Market GrowthAugust 29, 2024 | markets.businessinsider.comSee More Headlines EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? EyePoint Pharmaceuticals' stock was trading at $23.11 on January 1st, 2024. Since then, EYPT shares have decreased by 51.8% and is now trading at $11.15. View the best growth stocks for 2024 here. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.03. The firm had revenue of $9.48 million for the quarter, compared to analysts' expectations of $11.61 million. EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative trailing twelve-month return on equity of 43.24%. When did EyePoint Pharmaceuticals' stock split? EyePoint Pharmaceuticals's stock reverse split on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are EyePoint Pharmaceuticals' major shareholders? Top institutional investors of EyePoint Pharmaceuticals include Essex Investment Management Co. LLC (0.27%), Woodstock Corp (0.13%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Ew Healthcare Partners, LP, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine and David R Guyer. View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that EyePoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings8/07/2024Today10/17/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees120Year Founded1987Price Target and Rating Average Stock Price Target$29.00 High Stock Price Target$44.00 Low Stock Price Target$15.00 Potential Upside/Downside+160.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,790,000.00 Net Margins-172.29% Pretax Margin-172.13% Return on Equity-43.24% Return on Assets-29.72% Debt Debt-to-Equity RatioN/A Current Ratio4.75 Quick Ratio4.69 Sales & Book Value Annual Sales$50.39 million Price / Sales11.52 Cash FlowN/A Price / Cash FlowN/A Book Value$5.66 per share Price / Book1.97Miscellaneous Outstanding Shares52,084,000Free Float50,981,000Market Cap$580.74 million OptionableOptionable Beta1.57 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:EYPT) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.